Real-World Healthcare Resource Utilization in Patients with Indolent Non-Hodgkin's Lymphoma: Differences between Patients Treated First-Line with Ibrutinib or Bendamustine plus Rituximab

被引：0
|
作者：
Irwin, Debra [1 ,2 ]
Zhang, Lu [3 ]
Wilson, Kathleen [3 ]
Hoehn, Gerard [4 ]
Szabo, Erika [4 ]
Tang, Boxiong [5 ]
机构：
[1] Truven, Ann Arbor, MI USA
[2] IBM Co, Ann Arbor, MI USA
[3] Truven Hlth Analyt, Cambridge, MA USA
[4] Teva Pharmaceut, Malvern, PA USA
[5] Teva Pharmaceut Inc, Frazer, PA USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-113093
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3549
引用
下载
收藏
页数：3
相关论文
共 50 条
  • [41] Bendamustine pharmacokinetic profile and exposure–response relationships in patients with indolent non-Hodgkin’s lymphoma
    Joel S. Owen
    Murad Melhem
    Julie A. Passarell
    Denise D’Andrea
    Mona Darwish
    Bradley Kahl
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 1039 - 1049
  • [42] Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy
    Hornberger, John
    Chien, Rebecca
    Friedmann, Mark
    Han, Leona
    Shewade, Ashwini
    Satram-Hoang, Sacha
    Reyes, Carolina
    LEUKEMIA & LYMPHOMA, 2012, 53 (12) : 2371 - 2377
  • [43] BENDAMUSTINE IN ELDERLY PATIENTS WITH INDOLENT NON-HODGKIN'S LYMPHOMA: A REPORTED EXPERIENCE IN ROUTINE PRACTICE ON 76 PATIENTS
    Razurel, A.
    Amorin, S.
    Tiv, M.
    Zine, M.
    Biard, L.
    Harel, S.
    Brice, P.
    Madelaine, I.
    Thieblemont, C.
    HAEMATOLOGICA, 2015, 100 : 708 - 708
  • [44] Effectiveness of Bendamustine-Rituximab Compared to R-CHOP/R-CVP as a First-Line Treatment of Indolent Non-Hodgkin's Lymphoma or Mantle-Cell Lymphoma
    Edina, Brenda Cristie
    Rinaldi, Ikhwan
    ACTA MEDICA INDONESIANA, 2022, 54 (02) : 316 - 323
  • [45] A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study
    Matsumoto, Kimihiro
    Takayama, Nobuyuki
    Aisa, Yoshinobu
    Ueno, Hironori
    Hagihara, Masao
    Watanabe, Kentaro
    Nakaya, Aya
    Chen, Kenko
    Shimizu, Takayuki
    Tsukada, Yuiko
    Yamada, Yuji
    Nakazato, Tomonori
    Ishida, Akaru
    Miyakawa, Yoshitaka
    Yokoyama, Kenji
    Nakajima, Hideaki
    Masuda, Yoshihiro
    Yano, Takahiro
    Okamoto, Shinichiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (06) : 554 - 562
  • [46] A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study
    Kimihiro Matsumoto
    Nobuyuki Takayama
    Yoshinobu Aisa
    Hironori Ueno
    Masao Hagihara
    Kentaro Watanabe
    Aya Nakaya
    Kenko Chen
    Takayuki Shimizu
    Yuiko Tsukada
    Yuji Yamada
    Tomonori Nakazato
    Akaru Ishida
    Yoshitaka Miyakawa
    Kenji Yokoyama
    Hideaki Nakajima
    Yoshihiro Masuda
    Takahiro Yano
    Shinichiro Okamoto
    International Journal of Hematology, 2015, 101 : 554 - 562
  • [47] A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma
    Luminari, Stefano
    Goldaniga, Maria
    Cesaretti, Marina
    Orsucci, Lorella
    Tucci, Alessandra
    Pulsoni, Alessandro
    Salvi, Flavia
    Arcaini, Luca
    Carella, Angelo Michele
    Tedeschi, Alessandra
    Pinto, Antonello
    Stelitano, Caterina
    Baldini, Luca
    LEUKEMIA & LYMPHOMA, 2016, 57 (04) : 880 - 887
  • [48] Bendamustine Produces Durable Responses With an Acceptable Safety Profile in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma
    Cheson, Bruce D.
    Friedberg, Jonathan W.
    Kahl, Brad S.
    Van der Jagt, Richard H.
    Tremmel, Lothar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (06): : 452 - 457
  • [49] Real-World Efficacy and Safety of Rituximab, Lenalidomide and Ibrutinib Combination in Patients with Relapsed and/or Refractory Non- Hodgkin Lymphoma
    Koyun, Derya
    Sahin, Ugur
    Gokmen, Ayla
    Ozcan, Muhi. T.
    BLOOD, 2023, 142
  • [50] GADOLIN: PRIMARY RESULTS FROM A PHASE III STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE COMPARED WITH BENDAMUSTINE ALONE IN PATIENTS WITH RITUXIMAB-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA
    Sehn, L.
    Chua, N.
    Mayer, J.
    Dueck, G.
    Trneny, M.
    Bouabdallah, K.
    Fowler, N.
    Delwail, V.
    Press, O.
    Salles, G.
    Gribben, J.
    Lennard, A.
    Lugtenburg, P.
    Franklin, N.
    Wassner-Fritsch, E.
    Fingerle-Rowson, G.
    Cheson, B.
    HAEMATOLOGICA, 2015, 100 : 273 - 273
12345